Clinical Trials Browser

NCT04709380 2025-02-26

Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT

Phase 3 Terminated

36 enrolled

Gastrointestinal

Radiotherapy

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Clinical Trials

Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer

The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma

MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma

AflacLL1901 (CHOA-AML)

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

HCC

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma

YES-P

SOLACE

Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)

TSAP

Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer

SORAGO-HCC

Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery

2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer

Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection

BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma

Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy

Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma

Epigenetic Reprogramming in Relapse AML

The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial

Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer

Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer

Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer

Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma

Personalized Targeted Inhibitors Treatment in Renal Cell Cancer

TOKIO

Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy

A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer

Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer

A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer

SOAP

A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer

Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC

RAD 0901

Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma

HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)

Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer

Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer

Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer

Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)